Themis is developing novel vaccines for high burden infectious diseases and oncology applications.
Total raised: $67.2M
Investors 5
| Date | Name | Website |
| - | Weber Inve... | weberinves... |
| - | Adjuvant C... | adjuvantca... |
| - | Wellington... | wellington... |
| - | Hadean Ven... | hadeanvent... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 18.09.2019 | Series D | $44.12M | Hadean Ven... |
| 04.01.2018 | Series C | $12.07M | - |
| 05.09.2017 | - | $3.91M | - |
| 21.05.2011 | Series A | $7.1M | - |
Mentions in press and media 23
| Date | Title | Description |
| 26.04.2021 | Vienna: Europe’s underestimated innovation hotspot | Austria ~ Company: With almost 200 000 highly-educated and multi-linguistic students, out of which 30% are international talents, attractive geographical location at the heart of CEE, a population with high purchasing power which makes for ... |
| 03.06.2020 | Joint against malaria: European Investment Bank, European Commission and Investitionsbank Berlin inaugurate €70 million fund | Berlin, Luxembourg, 3 June 2020. Today, the European Investment Bank (EIB), the European Commission and Investitionsbank Berlin (IBB) announced the first closing of their EU Malaria Fund. The European Commission and the European Investment ... |
| 26.05.2020 | Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year | Merck, one of the largest vaccine makers in the world, is entering the Covid-19 arena with an announcement on Tuesday it is developing two different vaccines for Covid-19 and is also licensing an oral drug that might treat the virus. Merck ... |
| 14.05.2020 | Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France | Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an a... |
| 17.04.2020 | Themis announces Iain Dukes to join the company’s supervisory board | Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology companies. As Themis transitions towards rapidly ramping up the development of a coronavirus vaccine candidate towards the clinic in response ... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 01.10.2019 | Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial | Themis announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Instit... |
| 18.09.2019 | Themis raises €40M to run phase 3 chikungunya vaccine trial | Themis has raised €40 million ($44 million). The Merck-backed series D positions Themis to take its chikungunya vaccine through a phase 3 trial and move the lead candidate from its immuno-oncology R&D program into humans. Austria’s Them... |
| 18.09.2019 | Themis Secures €40M in Series D Financing | Themis, a Vienna, Austria-based developer of a vaccine for Chikungunya, secured €40M in Series D financing. The round was co-led by new investors, Farallon Capital and Hadean Ventures. MSD (tradename of Merck & Co., Inc., Kenilworth, N.... |
| 18.09.2019 | Themis raises €40M to run phase 3 chikungunya vaccine trial W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Themis has raised €40 million ($44 million). The Merck-backed series D positions Themis to take its chikungunya vaccine through a phase 3 trial and move the lead candidate from its immuno-oncology R&D program into humans. Sponsored by A... |
Show more